|
A retrospective cohort study to monitor real-world safety in patients with locally advanced or metastatic urothelial carcinoma (LA/mUC) treated with sacituzumab govitecan (SG) in the United States. |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb; Exelixis; Natera; OncoCyte; Sanofi/Aventis; Seagen |
Research Funding - Karyopharm Therapeutics |
|
|
Employment - Gilead Sciences; Gilead Sciences |
Leadership - Totality Home Heath Care Agency |
Stock and Other Ownership Interests - Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Employment - 4D Molecular Therapeutics (I); Genentech; Gilead Sciences; Santen (I) |
Stock and Other Ownership Interests - Gilead Sciences; Roche |
|
|
No Relationships to Disclose |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Employment - Genentech/Roche; Gilead Sciences |
Stock and Other Ownership Interests - Genentech/Roche; Gilead Sciences |
Patents, Royalties, Other Intellectual Property - Employed by Genentech, a member of the Roche group. |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Employment - Gilead Sciences; Roche/Genentech |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |